These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 3330095)

  • 21. Thymopentin in experimental and clinical medicine.
    Surv Immunol Res; 1985; 4 Suppl 1():1-156. PubMed ID: 3898279
    [No Abstract]   [Full Text] [Related]  

  • 22. Thymopentin (TP-5) in the treatment of rheumatoid arthritis.
    Kantharia BK; Goulding NJ; Hall ND; Davies J; Maddison PJ; Bacon PA; Farr M; Wojtulewski JA; Englehart KM; Liyanage SP
    Br J Rheumatol; 1989 Apr; 28(2):118-23. PubMed ID: 2650797
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stimulation by thymopoietin oligopeptides of lectin-dependent cell-mediated cytotoxicity in patients with systemic lupus erythematosus.
    Perl A; Gonzalez-Cabello R; Nékám K; Gergely P; Fehér J
    J Clin Lab Immunol; 1985 Nov; 18(3):119-22. PubMed ID: 3910838
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stabilized analogs of thymopentin. 2. 1,2- and 3,4-ketomethylene pseudopeptides.
    DeGraw JI; Almquist RG; Hiebert CK; Judd AK; Dousman L; Smith RL; Waud WR; Uchida I
    J Med Chem; 1997 Jul; 40(15):2398-406. PubMed ID: 9240354
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of thymopentin treatment on the relapse rate in frequently relapsing herpes simplex virus infections.
    Haneke E; Bolla K; Degreef H; Djawari D; Demaubeuge J; Molin L; Panconesi E; Schöpf E; Stengel R; Stingl G
    Int J Clin Pharmacol Res; 1984; 4(6):439-43. PubMed ID: 6085327
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thymopentin treatment in genital warts of long duration.
    Fransen L; Anthoons J; Hoogewijs G; Bolla K
    Cancer Detect Prev; 1988; 12(1-6):503-9. PubMed ID: 3052838
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Efficacy and tolerability of thymopoietin in patients at risk of infection].
    Recenti Prog Med; 1987; 78(7-8):358-64. PubMed ID: 3321257
    [No Abstract]   [Full Text] [Related]  

  • 28. Effects of thymopoietin pentapeptide (TP-5) on in vitro and in vivo IgE production by atopic dermatitis cell subsets.
    Cooper KD; Kang K; Hanifin JM
    Diagn Immunol; 1983; 1(3):211-5. PubMed ID: 6388971
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of the thymic factor, thymostimulin (TP-1), on the survival rate of tumor-bearing mice.
    Klein AS; Shoham J
    Cancer Res; 1981 Aug; 41(8):3217-21. PubMed ID: 7248976
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Methods of immunosuppression for study of growth and lung colony formation by human tumor cells in mice.
    Kovnat A; Khoo K; Selby P; Tannock I
    Cancer Res; 1986 Apr; 46(4 Pt 1):1617-22. PubMed ID: 3512076
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structural requirements for the biological activity of thymopentin analogs.
    Heavner GA; Audhya T; Kroon D; Goldstein G
    Arch Biochem Biophys; 1985 Oct; 242(1):248-55. PubMed ID: 2996431
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Thymopentin treatment of ovarian carcinoma: preliminary clinical results].
    Garozzo G; Granà G; Lomeo E; La Greca M; Castiglione MG; Caruso M; Curatolo M; Gurgone P
    G Ital Oncol; 1988; 8(1):11-3. PubMed ID: 3065223
    [No Abstract]   [Full Text] [Related]  

  • 33. [Model for acquired immunodeficiency caused by anesthesia and surgical procedures. Effect of treatment with thymopoietin pentapeptide (TP5)].
    Auteri A; D'Aniello C; Falotico N; Saletti M; Di Perri T
    Recenti Prog Med; 1986 Sep; 77(9):423-8. PubMed ID: 3541085
    [No Abstract]   [Full Text] [Related]  

  • 34. Thymopentin in active rheumatoid arthritis. An open, monitored study in 16 patients.
    Franchimont P; Hauwaert C; Bolla K
    Surv Immunol Res; 1985; 4 Suppl 1():81-6. PubMed ID: 3898297
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhancement by cyclophosphamide of experimental pulmonary metastases formation of Lewis lung carcinoma. I. Dose-dependence and kinetics of cyclophosphamide effect.
    Strzadała L; Rak J; Kuśnierczyk H
    Arch Immunol Ther Exp (Warsz); 1985; 33(6):825-9. PubMed ID: 3833119
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Correction of lipid peroxidation in stress with the peptide bioregulator thymopentin].
    Deviatkina TA; Brechko VV; Tarasenko LM; Zviago'lskaia IN; Bezuglyĭ IuV; Rituma IR; Klusha VE
    Fiziol Zh (1978); 1989; 35(5):14-8. PubMed ID: 2687033
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Thymopentin and immune response in patients with cancer].
    Petronella P; Ferrone R; Freda F; Valeriani G
    Minerva Chir; 1989 Sep; 44(18):2017-20. PubMed ID: 2694011
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of subcutaneous thymopentin treatment in drug addicts with persistent generalized lymphadenopathy.
    Barcellini W; Meroni PL; Frasca D; Sguotti C; Borghi MO; Uberti-Foppa C; Buzzetti P; Lazzarin A; Doria G; Moroni M
    Clin Exp Immunol; 1987 Mar; 67(3):537-43. PubMed ID: 3301099
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thymopentin in chronic Trichophyton rubrum infection.
    Molin L; Bolla K
    Surv Immunol Res; 1985; 4 Suppl 1():135-8. PubMed ID: 3898286
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potent cyclic peptide inhibitors of VLA-4 (alpha4beta1 integrin)-mediated cell adhesion. Discovery of compounds like cyclo(MePhe-Leu-Asp-Val-D-Arg-D-Arg) (ZD7349) compatible with depot formulation.
    Dutta AS; Gormley JJ; Coath M; Hassall L; Hayward CF; Gellert PR; Kittlety RS; Alcock PJ; Ferguson R; Halterman T; Jamieson A; Moors JA; Moores JM; Rees A; Wood LJ; Reilly CF; Haworth D
    J Pept Sci; 2000 Aug; 6(8):398-412. PubMed ID: 10969869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.